Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × trastuzumab deruxtecan × Gynecologic × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 4 Endometrial Neoplasms 4 Salivary Gland Neoplasms 2 Prostatic Neoplasms 2 Pancreatic Neoplasms 2 Breast Neoplasms 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Thyroid Neoplasms 1 Testicular Neoplasms 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Recurrence 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Neoplasms 1 Neoplasm Metastasis 1 Mouth Neoplasms 1 Melanoma 1 Liver Neoplasms 1 Head and Neck Neoplasms 1 Glioma 1 Gastrointestinal Stromal Tumors 1 Gastrointestinal Neoplasms 1 Gallbladder Neoplasms 1 Fallopian Tube Neoplasms 1

Interventions

Carboplatin 18 Paclitaxel 17 Cisplatin 9 Cyclophosphamide 7 Bevacizumab 6 Topotecan 5 Gemcitabine 5 pembrolizumab 4 olaparib 4 Letrozole 4 Interleukin-2 4 Doxorubicin 4 Albumin-Bound Paclitaxel 4 rucaparib 3 liposomal doxorubicin 3 fludarabine 3 durvalumab 3 chiauranib 3 cemiplimab 3 camrelizumab 3 Itraconazole 3 Injections 3 Hyperthermic Intraperitoneal Chemotherapy 3 Everolimus 3 Drug Therapy 3 pazopanib 2 iniparib 2 eprenetapopt 2 avelumab 2 apatinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07340164 2026-01-14

TROY

Yonsei University

Phase 2 Not yet recruiting

Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡